International registry highlights impact of POTELIGEO in rare lymphoma subtypes
Category: News
Early data from novel immunotherapy drug shows tumour response in resistant cancers
Global Fund welcomes private sector support ahead of phase 8 replenishment summit
Subcutaneous therapy delivers 45 percent response rate in difficult-to-treat patients
CHMP backs once-weekly subcutaneous option for systemic lupus erythematosus
Seven new technologies selected to help transform NHS care and speed up diagnosis
Designation supports phase 3 launch in watch-and-wait patients in 2026
Applied Research Collaborations to drive innovation and tackle inequalities across England
BioChaperone Lispro demonstrates improved post-meal glucose control compared to Humalog
